Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(IghMyc)22Bri transgene insertion 22, Ralph L Brinster MGI:2447604 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
58 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 15-fold
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
• compared with Tg(IghMyc)22Bri mice
|
|
• compared with Tg(IghMyc)22Bri mice
• however, the range to tumor types is the same
|
|
• 15-fold
|
|
• 15-fold
|
|
• 7.5-fold compared with Tg(IghMyc)22Bri mice
|
|
• 60-fold compared with Cd79atm1(Cre)Reth/Cd79a+ or Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• greater than 50-fold
|
|
• compared with Tg(IghMyc)22Bri mice
|
|
• greater than 50-fold
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 N |
• mice exhibit increased survival compared to Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• peripheral white blood counts are lower than in Tg(IghMyc)22Bri mice that develop leukemia
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• peripheral white blood counts are lower than in Tg(IghMyc)22Bri mice that develop leukemia
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
• compared to in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival is 9 weeks
|
|
• lymphomagenesis is accelerated compared to in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice show accelerated development of B-cell lymphomas, with a median survival of 94 days versus 113 days in single Tg(IghMyc)22Bri mice
• however, no difference in tumor load or in proliferation are seen and no differences in cell cycle profiles or apoptotic index are seen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die prior to 20 weeks of age
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of 31 days
|
|
• based on median survival time, mice carrying single Trp53tm1Brd allele were no more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of >130 days
|
|
• similar to mice carrying double Ppm1dtm1Lad allele without Cdkn2atm1Cjs allele, based on increased median survival time, mice carrying single Cdkn2atm1Cjs allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of 69 days
|
|
• based on median survival time, mice carrying double Atmtm1Awb allele were no more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• similar to mice with a null Trp53 allele, mice exhibit shorter survival than those with wild-type Trp53
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• on a hybrid background presence of a single Crebbtm2Pkb allele decreased the median survival time by about 8-10 weeks compared to wild-type transgenic littermates
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• lymphoma-free survival is 85.1 months compared with 126.4 months for Tg(IghMyc)22Bri mice
|
|
• lymphoma cell clusters spread throughout the liver parenchyma and exhibit various degrees of lung and pancreas infiltration unlike in Tg(IghMyc)22Bri mice
|
|
• mice develop lymphomas by 25 days of age
• 3 of 5 mice younger than 2 months of age develop lymphomas unlike Tg(IghMyc)22Bri mice
• by 5 months, 10 of 10 of mice develop lymphomas compared with 6 of 9 Tg(IghMyc)22Bri mice
|
|
• all lymphomas are B cell or pre-B cell lymphomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• lymphoma-free survival is 108.9 months compared with 126.4 months for Tg(IghMyc)22Bri mice
|
|
• lymphoma cell clusters spread throughout the liver parenchyma and exhibit various degrees of lung and pancreas infiltration unlike in Tg(IghMyc)22Bri mice
|
|
• 3 of 5 mice younger than 2 months of age develop lymphomas unlike Tg(IghMyc)22Bri mice
• by 5 months, 16 of 20 of mice develop lymphomas compared with 6 of 9 Tg(IghMyc)22Bri mice
|
|
• all lymphomas are B cell or pre-B cell lymphomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean mortality is 10 weeks
|
|
• by 8 weeks
|
|
• development of lymphoma is accelerated compared to in Tg(IghMyc)22Bri mice
|
|
• lymphomas are composed of large pre-B cells unlike in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• compared with Tg(IghMyc)22Bri mice
• median survival is 10 days longer than in Trp53tm1Thst/Trp53+ Tg(IghMyc)22Bri mice
|
|
• with increased apoptosis and senescence staining in tumors from Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die prior to 30 weeks of age
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
• tumor cells exhibit replacement of the knock-out allele with a wild-type allele
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
• however, DNA damage repair following ionizing radiation exposure is normal
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
• however, DNA damage repair following ionizing radiation exposure is normal
|
|
• B cells exhibit severely impaired Myc-induced DNA damage repair
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• compared with Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all lymphomas have numerical chromosomal abnormalities unlike in Tg(IghMyc)22Bri animals, however only 1 of 4 tumors show structural abnormalities that are seen in the transgenic mice alone
|
|
• B cell lymphoma onset is significantly accelerated compared to Tg(IghMyc)22Bri mice
• all lymphomas have numerical chromosomal abnormalities unlike Tg(IghMyc)22Bri animals, however only 1 of 4 tumors show structural abnormalities that are seen in the transgenic mice alone
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• without doxycycline treatment median survival is 82 days, with doxycycline treatment the improves to 145 days
|
|
• in the absence of doxycycline, lymphoblastic leukemia is seen by 2 weeks of age
• in 5 - 7 week old triple transgenics with lymphoblastic leukemia doxycycline treatment resulted in normalization of the WBC count and restoration of normal hematopoiesis
|
|
• bulky B cell derived lymphomas, similar to those in Tg(IghMyc)22Bri single transgenics, are seen in older triple transgenics after treatment with doxycycline
|
|
• transgenics with leukemia are lethargic, doxycycline treatment returns activity levels to normal
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
|
• increase in survival as compared to mice carrying Tg(IghMyc)22Bri alone and mice carrying Tg(IghMyc)22Bri and heterozygous for Mirc1tm2.1Aven
|
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
|
• bone marrow of 5 week old mice is not characterized by an accumulation of pre-B cells as compared to Tg(IghMyc)22Bri
|
|
• increase in pre-B cell apoptosis as compared to mice carrying Tg(IghMyc)22Bri alone
|
|
• bone marrow of 5 week old mice is not characterized by an accumulation of pre-B cells as compared to Tg(IghMyc)22Bri
|
|
• immunophenotype of B cell lymphomas is altered (increase in in IgM+ tumors) as compared to Tg(IghMyc)22Bri alone
|
|
• as compared to mice carrying only Tg(IghMyc)22Bri
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• on a C57BL/6 background, surivival of transgenic mutants carrying the mutant Ep300 allele were identical to that of Ep300-sufficient transgenic mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice develop B cell lymphomas
• however, lymphomagenesis is delayed compared to in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• on a hybrid background presence of a single Ep300tm3Pkb allele decreased the median survival time by about 8-10 weeks compared to wild-type transgenic littermates
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of 130 days
|
|
• similar to mice carrying double Ppm1dtm1Lad allele without Mapk14tm1Dvb allele, based on increased median survival time, mice carrying single Mapk14tm1Dvb allele were considerably more resistant to tumor formation induced by myc than mice with homozygous wild-type Ppm1d+ allele
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of 107 days
|
|
• mice carrying a single Ppm1dtm1Lad allele were considerably more resistant to tumor formation induced by myc than wild-type transgenic litter mates based on increased median survival time by about 30 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• the median lifespan of 138 days
|
|
• mice carrying double Ppm1dtm1Lad allele were considerably more resistant to tumor formation induced by myc than wild-type transgenic litter mates based on increased median survival time by about 60 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die prior to 20 weeks of age
|
|
• mice exhibit an earlier age of onset and enhanced penetrance of B cell lymphomas compared to in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• accelerated tumor formation as compared to mice carrying only Tg(IghMyc)22Bri
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• delayed onset of B cell lymphoma compared with Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• accelerated development of plasmacytomas compared to single Tg(Igh-Abl1)40Sco transgenic mice, with mice becoming ill between 5 and 8 weeks of age; especially prominent in the intestine
• tumors are oligoclonal and often secrete IgM
• however, double transgenics do not develop pre-B or B lymphomas, as observed in single Tg(IghMyc)22Bri mice
|
|
• 64% of transgenics exhibit enlarged mesenteric lymph nodes due to engorgement with plasmacytoma cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• animals become terminally ill at 5-6 weeks of age
|
|
• masses of lymphoblasts occupy the spleen, lymph nodes and thymus and extensively invade the bone marrow, liver, lungs, and kidneys, an indication of malignant lymphoma
• tumors derive from a cell with the hallmarks of a primitive hematopoietic cell
|
|
• 50- to 100-fold higher levels of white blood cells compared to controls
|
|
• enlarged B cells
|
|
• 70% increase in numbers of B cells in bone marrow and spleen
|
|
• enlarged pre-B cells
|
|
• 30% increase in numbers of pre-B cells in bone marrow and spleen
|
|
• 50- to 100-fold higher levels of white blood cells compared to controls
|
|
• enlarged B cells
|
|
• 70% increase in numbers of B cells in bone marrow and spleen
|
|
• enlarged pre-B cells
|
|
• 30% increase in numbers of pre-B cells in bone marrow and spleen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• lymphomas develop significantly earlier in these mice than in mice carrying the transgene on a wild-type background
• the mean time of onset is 7 weeks earlier than in the control group with all mice have detectable tumors by 30 weeks of age
• the tumors consist of a mix pre-B and B cells lymphomas
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 50% of double transgenics die of a lymphoproliferative disorder by 5.5 weeks
|
|
• multifocal to coalescent infiltrations of mononuclear cells with large round to polygonal hypochromatic nuclei are seen in the kidneys, spleen, lymph node, liver, ung, heart, thymus, pancreas, and sternal bone marrow
|
|
• osteolytic lesions with cheets of pleomorphic plasmacytic cells adjacent to lysed osseous trabeculae are seen
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
• the number of immature/transitional B cells is increased
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
• the number of immature/transitional B cells is increased
|
|
• multiple beige nodules up to 2 mm in diameter are seen
|
|
• 4 - 6 week old double transgenic exhibit severe splenomegaly
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• about 60% of mice live beyond 200 days at which point most mice carrying the transgene alone have died
|
|
|
• dramatic delay in tumor initiation compared to mice carrying the transgene alone
|
|
N |
• overall rate of protein synthesis in B lymphocytes is reduced towards normal levels unlik in mice carrying Tg(IghMyc)22Bri alone
|
|
|
• B lymphocytes show increased glucose uptake and increased rate of glucose oxidation compared to mice carrying the transgene alone
• no alterations in mitochondrial mass or mitochondrial membrane potential are detected
|
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
|
|
• B lymphocytes show increased glucose uptake and increased rate of glucose oxidation compared to mice carrying the transgene alone
• no alterations in mitochondrial mass or mitochondrial membrane potential are detected
|
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
|
|
• dramatic increase in B lymphocytes compared to mice carrying the transgene alone
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median lifespan is 110 days, which is similar to single Tg(IghMyc)22Bri hemizygotes
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival of 50 days
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• average survival is 70 days; survival is decreased compared to single Tg(IghMyc)22Bri hemizygotes which live to about 100 days
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~55%) and sIg+ B lymphoma (~45%)
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival of 58 days
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~60%) and sIg+ B lymphoma (~40%)
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
• increase in white blood cell count is higher than in single Tg(IghMyc)22Bri hemizygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival is 64 days; survival is decreased compared to single Tg(IghMyc)22Bri hemizygotes which live to about 100 days
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
• mutants exhibit a mixture of sIg- pre-B lymphoma (~65%) and sIg+ B lymphoma (~35%)
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
• white blood cell counts are increased to a similar extent as in single Tg(IghMyc)22Bri hemizygotes
|
|
• mutants exhibit a rare incidence of Thy1+ T lymphoma
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median lifespan is 84 days, which is not statistically different from single Tg(IghMyc)22Bri hemizygotes
|
|
• mutants exhibit a mix of sIg- pre-B lymphoma (~50%) and sIg+ B lymphoma (~50%)
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mutants become moribund without a large peripheral tumor burden, with a median survival of 82 days
|
|
• mutants develop lymphoma, with latency of tumorigenesis reduced compared to single Tg(IghMyc)22Bri/0 mice
• lymphoma-bearing mice treated with doxycycline at the onset of paralysis regain full movement within 2 days of doxycycline treatment, show tumor involution, and live for a further 24-64 days before tumors relapse
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• spleen is enlarged and taken over by B220+ IgM- (pre-B) tumor cells, with lymphoma dissemination into the lymph nodes and liver
|
|
• partial hind leg paralysis is seen in some mutants, most likely attributed to lymphoma
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• of B220+CD43+ Emu-Myc pre-B cells
|
|
• of B220+CD43+ Emu-Myc pre-B cells
|
|
• of B220+CD43+ Emu-Myc pre-B cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• as in Tg(IghMyc)22Bri mice
|
|
• as in Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean survival after lymphomas develop is 268 days compared to 91 days in Tg(IghMyc)22Bri mice and 101 days in Tg(IghMyc)22Bri Cks1btm1Sir heterozygotes
|
|
• only 1 of 9 diseased mice show moderate bone marrow infiltration and none presented with liver or meningeal infiltrates present in Tg(IghMyc)22Bri mice
|
|
• delayed development of lymphomas compared to Tg(IghMyc)22Bri mice
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
• 5.4+/-0.4x106ul compared to 6.9+/-0.4x106ul in Tg(IghMyc)22Bri mice
|
|
• at 4 weeks, mice have significantly smaller spleens than Tg(IghMyc)22Bri counter parts (83+/-11mg compared to 157+/-7mg)
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
• 5.4+/-0.4x106ul compared to 6.9+/-0.4x106ul in Tg(IghMyc)22Bri mice
|
|
• at 4 weeks, mice have significantly smaller spleens than Tg(IghMyc)22Bri counter parts (83+/-11mg compared to 157+/-7mg)
|
|
• severely impaired proliferative response compared to Tg(IghMyc)22Bri mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean survival after lymphomas development is 101 days
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Pro-B tumor in Pknox1tm1Ngc/Pknox1+ Tg(IghMyc)22Bri/0 mice
|
• median survival time is 23 weeks compared with 58 weeks for Tg(IghMyc)22Bri mice
|
|
• in the spleen
|
|
• in the spleen
|
|
• accelerated and enhanced immature B cell lymphomas compared with Tg(IghMyc)22Bri mice
|
|
• in the spleen
|
|
• in the spleen
|
|
• in the spleen
|
|
• in the spleen
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• onset of lymphoma is accelerated compared to single Tg(IghMyc)22Bri transgenic mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• onset of lymphoma is accelerated compared to single Tg(IghMyc)22Bri transgenic mice and is evident at less than 1 month of age
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
|
• reduction in apoptosis of splenic B cells at 3 weeks of age, before lymphoma occurrence, compared to single Tg(IghMyc)22Bri transgenic mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• median survival is 20 weeks
|
|
• moderately at 4 weeks of age
|
|
• moderately at 4 weeks of age
|
|
• moderately at 4 weeks of age
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
|
• almost all mice die by 200 days of age
|
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
|
|
• in B lymphocytes compared to wild-type controls but reduced compared to mice carrying the transgene and homozygous for Prps2tm1a(KOMP)Wtsi
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice die at 6 to 15 weeks of age with 94% of mice dying by 4 months of age
(J:78177)
• median survival is 100 days
(J:186117)
|
|
• mice occasionally develop thyoma without involvement of peripheral lymphoid organs
|
|
• mice develop multicentric lymphosarcoma associated with leukemia
|
|
• 13 of 15 mice develop lymphomas
(J:78177)
• mice develop multicentric lymphosarcoma associated with leukemia
(J:78177)
|
|
• lymphomas develop from single B-lymphoid clones at different stages of differentiation
(J:78177)
• mutants exhibit a mixture of sIg- pre-B lymphoma (~40%) and sIg+ B lymphoma (~60%)
(J:186117)
|
|
• mice develop multicentric lymphosarcoma associated with leukemia
|
|
• two-fold
|
|
• mice exhibit an increased in the number of lymphoblasts in lymph tissues and the blood compared to wild-type mice
|
|
• white blood cell counts are increased
|
|
• bone marrow from 5 week old mice contains an accumulation of pre-B cells
|
|
• two-fold
|
|
• mice exhibit an increased in the number of lymphoblasts in lymph tissues and the blood compared to wild-type mice
|
|
• white blood cell counts are increased
|
|
• bone marrow from 5 week old mice contains an accumulation of pre-B cells
|
|
• two-fold
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| Burkitt lymphoma | DOID:8584 |
OMIM:113970 |
J:78177 , J:186117 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean mortality is 19 weeks
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mean survival after lymphomas develop 91 days
|
|
• 6 of 6 mice suffer from dissemination disease with diffuse bone marrow infiltration of B220+ lymphocytes and infiltration of the spleen, liver and meninges
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|
|
||
